nf2 men luc2 Search Results


4t1 mouse breast cancer model  (Jackson Laboratory)
86
Jackson Laboratory 4t1 mouse breast cancer model
Whole-body imaging of tumor-bearing mice with difference sizes of tumors after SC injection of Cy5-peptides. (A) Experimental design of fluorescence imaging with Cy5-FUD, Cy5-PEG-FUD, and Cy5-PEG-mFUD. (B) Representative images of fluorescence imaging of <t>4T1</t> tumor-bearing mice subcutaneously injected with Cy5-FUD, Cy5-PEG-FUD, and Cy5-PEG-mFUD at 1, 2, and 3 weeks after the tumor (green arrows) implantation. The images were acquired at 24 h post-injection. (C) Quantification of fluorescence intensity in tumors of the images from Fig. 4B . Net radiant efficiency was obtained by subtracting the background fluorescence intensity before injection each week (means ± SD, n = 4–5). (D) Ex vivo images of the organs harvested after the 3-week whole animal imaging time points. (E) Quantification of fluorescence intensity of the images from Fig. 4D (means ± SD, n = 4–5 per group). *: P < 0.05, **: P < 0.01, ***: P < 0.001. Fig. 4A created with BioRender.com .
4t1 Mouse Breast Cancer Model, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nf2+men+luc2/pmc09841600-74-3-15?v=Jackson+Laboratory
Average 86 stars, based on 1 article reviews
4t1 mouse breast cancer model - by Bioz Stars, 2026-08
86/100 stars
  Buy from Supplier

Image Search Results


Whole-body imaging of tumor-bearing mice with difference sizes of tumors after SC injection of Cy5-peptides. (A) Experimental design of fluorescence imaging with Cy5-FUD, Cy5-PEG-FUD, and Cy5-PEG-mFUD. (B) Representative images of fluorescence imaging of 4T1 tumor-bearing mice subcutaneously injected with Cy5-FUD, Cy5-PEG-FUD, and Cy5-PEG-mFUD at 1, 2, and 3 weeks after the tumor (green arrows) implantation. The images were acquired at 24 h post-injection. (C) Quantification of fluorescence intensity in tumors of the images from Fig. 4B . Net radiant efficiency was obtained by subtracting the background fluorescence intensity before injection each week (means ± SD, n = 4–5). (D) Ex vivo images of the organs harvested after the 3-week whole animal imaging time points. (E) Quantification of fluorescence intensity of the images from Fig. 4D (means ± SD, n = 4–5 per group). *: P < 0.05, **: P < 0.01, ***: P < 0.001. Fig. 4A created with BioRender.com .

Journal: Journal of controlled release : official journal of the Controlled Release Society

Article Title: Multimodal Imaging Demonstrates Enhanced Tumor Exposure of PEGylated FUD Peptide in Breast Cancer

doi: 10.1016/j.jconrel.2022.08.028

Figure Lengend Snippet: Whole-body imaging of tumor-bearing mice with difference sizes of tumors after SC injection of Cy5-peptides. (A) Experimental design of fluorescence imaging with Cy5-FUD, Cy5-PEG-FUD, and Cy5-PEG-mFUD. (B) Representative images of fluorescence imaging of 4T1 tumor-bearing mice subcutaneously injected with Cy5-FUD, Cy5-PEG-FUD, and Cy5-PEG-mFUD at 1, 2, and 3 weeks after the tumor (green arrows) implantation. The images were acquired at 24 h post-injection. (C) Quantification of fluorescence intensity in tumors of the images from Fig. 4B . Net radiant efficiency was obtained by subtracting the background fluorescence intensity before injection each week (means ± SD, n = 4–5). (D) Ex vivo images of the organs harvested after the 3-week whole animal imaging time points. (E) Quantification of fluorescence intensity of the images from Fig. 4D (means ± SD, n = 4–5 per group). *: P < 0.05, **: P < 0.01, ***: P < 0.001. Fig. 4A created with BioRender.com .

Article Snippet: To generate the 4T1 mouse breast cancer model, 8–10-week-old female Balb/C mice were purchased from Jackson Labs. For tumor cell inoculation, cells were harvested, washed in DPBS, then enumerated.

Techniques: Imaging, Injection, Fluorescence, Ex Vivo

Intravital imaging of Cy5-FUD and Cy5-PEG-FUD in 4T1 mouse mammary carcinoma. After two weeks of tumor growth, images were acquired pre and post- 24 h SC injection of Cy5- peptides. SHG (collagen fibers) shown in grey, Cy5 (peptide) shown in cyan and vasculature in red. (A) Representative image of Cy5-FUD and Cy5-PEG-FUD in the TME pre-injection and 24 h post-injection, respectively. Scale bar = 150 μm. (B) Quantification of mean intensity of Cy5-labeled peptides. (C) Zoomed inset of Cy5-PEG-FUD 24 h p.i. Yellow arrows indicate Cy5-peptides localizing to cellular structures. Scale bar = 50 μm, ns: non-significant, ***: P < 0.001.

Journal: Journal of controlled release : official journal of the Controlled Release Society

Article Title: Multimodal Imaging Demonstrates Enhanced Tumor Exposure of PEGylated FUD Peptide in Breast Cancer

doi: 10.1016/j.jconrel.2022.08.028

Figure Lengend Snippet: Intravital imaging of Cy5-FUD and Cy5-PEG-FUD in 4T1 mouse mammary carcinoma. After two weeks of tumor growth, images were acquired pre and post- 24 h SC injection of Cy5- peptides. SHG (collagen fibers) shown in grey, Cy5 (peptide) shown in cyan and vasculature in red. (A) Representative image of Cy5-FUD and Cy5-PEG-FUD in the TME pre-injection and 24 h post-injection, respectively. Scale bar = 150 μm. (B) Quantification of mean intensity of Cy5-labeled peptides. (C) Zoomed inset of Cy5-PEG-FUD 24 h p.i. Yellow arrows indicate Cy5-peptides localizing to cellular structures. Scale bar = 50 μm, ns: non-significant, ***: P < 0.001.

Article Snippet: To generate the 4T1 mouse breast cancer model, 8–10-week-old female Balb/C mice were purchased from Jackson Labs. For tumor cell inoculation, cells were harvested, washed in DPBS, then enumerated.

Techniques: Imaging, Injection, Labeling

(A) A schematic diagram of the experimental design of μPET/CT imaging. (B) Longitudinal PET images of 4T1 tumor-bearing mice after IV injection of 64 Cu-FUD, 64 Cu-PEG-FUD, and 64 Cu-PEG-mFUD (5 mg/kg). The images were acquired 2, 24, and 48 h p.i. The white arrows indicate the locations of the major organs, i.e., tumor, heart, liver, and kidneys. Fig. 7A created with BioRender.com .

Journal: Journal of controlled release : official journal of the Controlled Release Society

Article Title: Multimodal Imaging Demonstrates Enhanced Tumor Exposure of PEGylated FUD Peptide in Breast Cancer

doi: 10.1016/j.jconrel.2022.08.028

Figure Lengend Snippet: (A) A schematic diagram of the experimental design of μPET/CT imaging. (B) Longitudinal PET images of 4T1 tumor-bearing mice after IV injection of 64 Cu-FUD, 64 Cu-PEG-FUD, and 64 Cu-PEG-mFUD (5 mg/kg). The images were acquired 2, 24, and 48 h p.i. The white arrows indicate the locations of the major organs, i.e., tumor, heart, liver, and kidneys. Fig. 7A created with BioRender.com .

Article Snippet: To generate the 4T1 mouse breast cancer model, 8–10-week-old female Balb/C mice were purchased from Jackson Labs. For tumor cell inoculation, cells were harvested, washed in DPBS, then enumerated.

Techniques: Imaging, IV Injection

(A) In vivo μPET imaging analysis of 4T1 tumor-bearing mice after IV injection of 64 Cu-FUD, 64 Cu-PEG-FUD, and 64 Cu-PEG-mFUD shown in time-activity curves for heart, lung, tumor, kidneys, and liver (means ± SD, n = 4). (B) Analysis of ex vivo biodistribution of 64 Cu-FUD, 64 Cu-PEG-FUD, and 64 Cu-PEG-mFUD after IV injection. The activity remaining in organs at each time point at 48 h was presented as the percent injected activity per gram (%IA/g). *: P < 0.05, **: P <0.01, ***: P <

Journal: Journal of controlled release : official journal of the Controlled Release Society

Article Title: Multimodal Imaging Demonstrates Enhanced Tumor Exposure of PEGylated FUD Peptide in Breast Cancer

doi: 10.1016/j.jconrel.2022.08.028

Figure Lengend Snippet: (A) In vivo μPET imaging analysis of 4T1 tumor-bearing mice after IV injection of 64 Cu-FUD, 64 Cu-PEG-FUD, and 64 Cu-PEG-mFUD shown in time-activity curves for heart, lung, tumor, kidneys, and liver (means ± SD, n = 4). (B) Analysis of ex vivo biodistribution of 64 Cu-FUD, 64 Cu-PEG-FUD, and 64 Cu-PEG-mFUD after IV injection. The activity remaining in organs at each time point at 48 h was presented as the percent injected activity per gram (%IA/g). *: P < 0.05, **: P <0.01, ***: P <

Article Snippet: To generate the 4T1 mouse breast cancer model, 8–10-week-old female Balb/C mice were purchased from Jackson Labs. For tumor cell inoculation, cells were harvested, washed in DPBS, then enumerated.

Techniques: In Vivo, Imaging, IV Injection, Activity Assay, Ex Vivo, Injection